PMEL and melanoma: While there were no clear objective responses to VSV-IFNβ-TYRP1, dose-dependent immunogenicity to melanoma antigens was seen, both to virus-encoded TYRP1 and other melanoma antigens (gp100, hTERT, and cyclin D1), suggesting epitope spreading.